Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug DF9001 targets cancer cells in early trial

NCT ID NCT05597839

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 27 times

Summary

This study tested a new drug called DF9001 in 24 adults with advanced solid tumors that have not responded to other treatments. The drug works by helping the body's immune cells recognize and attack cancer cells. The main goals were to check safety and find the best dose, both when used alone and with another immunotherapy drug (pembrolizumab).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • AMR Kansas City

    Kansas City, Missouri, 64114, United States

  • Banner MD Anderson

    Gilbert, Arizona, 85234, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Mayo Clinic Arizona

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Minnesota

    Rochester, Minnesota, 55905, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

  • Rutgers

    New Brunswick, New Jersey, 08903, United States

  • UC Irvine Medical Center

    Irvine, California, 92617, United States

  • UMPC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

  • University of Louisville Hospital

    Louisville, Kentucky, 40202, United States

  • University of Wisconsin

    Madison, Wisconsin, 53792, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.